- Markets
- Healthcare
- KOBO
KOBO
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Kobo Biotech do?
Avon Organics Ltd specializes in producing Diketene, a fundamental component in various industries like pesticides, chemicals, pharmaceuticals, and dyestuffs. Their product range includes pharmaceutical, agrochemical, and pigment intermediates.
Who are the competitors of Kobo Biotech?
Kobo Biotech major competitors are Cian Healthcare, Senbo Industries, Shamrock Indl. Co, MPS Pharmaa, Adline Chem Lab, Fabino Enterprises, Ganga Pharma.. Market Cap of Kobo Biotech is ₹7 Crs. While the median market cap of its peers are ₹6 Crs.
Is Kobo Biotech financially stable compared to its competitors?
Kobo Biotech seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Kobo Biotech pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Kobo Biotech latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Kobo Biotech allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Kobo Biotech balance sheet?
Kobo Biotech balance sheet is weak and might have solvency issues
Is the profitablity of Kobo Biotech improving?
Yes, profit is increasing. The profit of Kobo Biotech is -₹5.46 Crs for TTM, -₹5.55 Crs for Mar 2023 and -₹15.23 Crs for Mar 2022.
Is the debt of Kobo Biotech increasing or decreasing?
Yes, The debt of Kobo Biotech is increasing. Latest debt of Kobo Biotech is ₹140 Crs as of Mar-24. This is greater than Mar-23 when it was ₹140 Crs.
Is Kobo Biotech stock expensive?
There is insufficient historical data to gauge this. Latest PE of Kobo Biotech is 0
Has the share price of Kobo Biotech grown faster than its competition?
Kobo Biotech has given lower returns compared to its competitors. Kobo Biotech has grown at ~-21.99% over the last 3yrs while peers have grown at a median rate of 15.18%
Is the promoter bullish about Kobo Biotech?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Kobo Biotech is 44.95% and last quarter promoter holding is 44.95%.
Are mutual funds buying/selling Kobo Biotech?
There is Insufficient data to gauge this.